Amended IN Senate March 27, 2019 CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION Senate Bill No. 706Introduced by Senator GalgianiFebruary 22, 2019 An act to amend Section 1695 of add Section 104101 to the Health and Safety Code, relating to public health. LEGISLATIVE COUNSEL'S DIGESTSB 706, as amended, Galgiani. Public health: neonatal group B streptococcal disease. pulmonary hypertension task force.Existing law requires the State Department of Public Health to conduct a program for the control of high blood pressure, also known as hypertension and that includes pulmonary hypertension.This bill would require the department to establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension, as specified. The bill would specify the composition and duties of the task force, including developing and updating a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension. The bill would require the task force to submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023.Existing law creates in the California Health and Human Services Agency the State Department of Health Care Services, which is vested with specified powers of the former State Department of Health Services. Existing law required the State Department of Health Services, to the extent that funds were available in the departments budget for the 199495 fiscal year, to convene a consensus conference to address the issue of testing or treatment to prevent neonatal group B streptococcal disease (chemoprophylaxis). Existing law required the State Department of Health Services to make every effort to obtain appropriate federal funds for this purpose, if the department determined that state funds were not available.This bill would make technical, nonsubstantive changes to that provision.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: NOYES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. Section 104101 is added to the Health and Safety Code, to read:104101. (a) The department shall establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension.(b) The task force shall do all of the following:(1) Develop and update a summary of the advances made in research on, and treatment and diagnosis of, pediatric pulmonary hypertension.(2) Develop and update a summary of the advances made in access to care for individuals with a diagnosis of pulmonary hypertension.(3) Monitor pulmonary hypertension research, services, and support activities across the state, including coordination of the states activities and programs with respect to pediatric pulmonary hypertension.(4) Develop and update a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension, including recommendations on how to do all of the following:(A) Advance research on pediatric and pulmonary hypertension.(B) Improve the transplantation criteria and process concerning both lung transplants and heart and lung transplants for individuals with a diagnosis of pulmonary hypertension.(C) Improve public awareness and recognition of pulmonary hypertension.(D) Improve health care delivery for individuals with a diagnosis of pulmonary hypertension.(E) Improve the early and accurate diagnosis of pediatric pulmonary hypertension.(F) Systematically advance the full spectrum of biomedical research on pulmonary hypertension.(5) Develop and update the progress made in implementing the comprehensive strategic plan developed pursuant to paragraph (4).(c) The task force shall be comprised of the following members:(1) The Secretary of California Health and Human Services or a designee, who shall serve as the chair of the task force.(2) The State Public Health Officer or a designee.(3) The Insurance Commissioner or a designee.(4) The Director of Health Care Services or a designee.(5) Eight additional members to be appointed by the secretary as follows:(A) Two representatives of the California Medical Association.(B) One representative of the California Association of Health Plans.(C) One representative from a commercial health insurance plan or managed care organization operating in the state.(D) One individual with a diagnosis of pulmonary hypertension or the parent or guardian of an individual with a diagnosis of pediatric pulmonary hypertension.(E) One representative of the California Chapter of the American College of Cardiology.(F) One representative of a pharmaceutical company that manufactures a drug or device for detecting, preventing, or treating pediatric pulmonary hypertension.(G) One representative of a research, advocacy, or support organization primarily serving individuals with a diagnosis of pediatric pulmonary hypertension.(d) Members of the task force shall serve without compensation. All administrative requirements for the production of the reports shall be completed by the California Health and Human Services Agency.(e) The task force shall submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023. The reports shall be submitted in compliance with Section 9795 of the Government Code.SECTION 1.Section 1695 of the Health and Safety Code is amended to read:1695.To the extent that funds are available in the State Department of Health Services budget for the 199495 fiscal year for this purpose, the department shall convene a consensus conference to address the issue of testing or treatment to prevent neonatal group B streptococcal disease (chemoprophylaxis). The conferees shall include, but not be limited to, representation from the California Chapter of the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists District IX, the California Medical Association, the California Conference of Local Health Officers, and the Group B Strep Association. The conference shall convene at least once during the 199495 fiscal year. The department shall develop, based on the proceedings of the consensus conference, a standardized written summary on group B streptococcal disease and guidelines on the prevention of neonatal group B streptococcal disease, no later than July 1, 1995. The department shall make every effort to obtain appropriate federal funds for this purpose, if the department determines that state funds are not available.
Amended IN Senate March 27, 2019 CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION Senate Bill No. 706Introduced by Senator GalgianiFebruary 22, 2019 An act to amend Section 1695 of add Section 104101 to the Health and Safety Code, relating to public health. LEGISLATIVE COUNSEL'S DIGESTSB 706, as amended, Galgiani. Public health: neonatal group B streptococcal disease. pulmonary hypertension task force.Existing law requires the State Department of Public Health to conduct a program for the control of high blood pressure, also known as hypertension and that includes pulmonary hypertension.This bill would require the department to establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension, as specified. The bill would specify the composition and duties of the task force, including developing and updating a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension. The bill would require the task force to submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023.Existing law creates in the California Health and Human Services Agency the State Department of Health Care Services, which is vested with specified powers of the former State Department of Health Services. Existing law required the State Department of Health Services, to the extent that funds were available in the departments budget for the 199495 fiscal year, to convene a consensus conference to address the issue of testing or treatment to prevent neonatal group B streptococcal disease (chemoprophylaxis). Existing law required the State Department of Health Services to make every effort to obtain appropriate federal funds for this purpose, if the department determined that state funds were not available.This bill would make technical, nonsubstantive changes to that provision.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: NOYES Local Program: NO
Amended IN Senate March 27, 2019
Amended IN Senate March 27, 2019
CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION
Senate Bill No. 706
Introduced by Senator GalgianiFebruary 22, 2019
Introduced by Senator Galgiani
February 22, 2019
An act to amend Section 1695 of add Section 104101 to the Health and Safety Code, relating to public health.
LEGISLATIVE COUNSEL'S DIGEST
## LEGISLATIVE COUNSEL'S DIGEST
SB 706, as amended, Galgiani. Public health: neonatal group B streptococcal disease. pulmonary hypertension task force.
Existing law requires the State Department of Public Health to conduct a program for the control of high blood pressure, also known as hypertension and that includes pulmonary hypertension.This bill would require the department to establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension, as specified. The bill would specify the composition and duties of the task force, including developing and updating a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension. The bill would require the task force to submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023.Existing law creates in the California Health and Human Services Agency the State Department of Health Care Services, which is vested with specified powers of the former State Department of Health Services. Existing law required the State Department of Health Services, to the extent that funds were available in the departments budget for the 199495 fiscal year, to convene a consensus conference to address the issue of testing or treatment to prevent neonatal group B streptococcal disease (chemoprophylaxis). Existing law required the State Department of Health Services to make every effort to obtain appropriate federal funds for this purpose, if the department determined that state funds were not available.This bill would make technical, nonsubstantive changes to that provision.
Existing law requires the State Department of Public Health to conduct a program for the control of high blood pressure, also known as hypertension and that includes pulmonary hypertension.
This bill would require the department to establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension, as specified. The bill would specify the composition and duties of the task force, including developing and updating a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension. The bill would require the task force to submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023.
Existing law creates in the California Health and Human Services Agency the State Department of Health Care Services, which is vested with specified powers of the former State Department of Health Services. Existing law required the State Department of Health Services, to the extent that funds were available in the departments budget for the 199495 fiscal year, to convene a consensus conference to address the issue of testing or treatment to prevent neonatal group B streptococcal disease (chemoprophylaxis). Existing law required the State Department of Health Services to make every effort to obtain appropriate federal funds for this purpose, if the department determined that state funds were not available.
This bill would make technical, nonsubstantive changes to that provision.
## Digest Key
## Bill Text
The people of the State of California do enact as follows:SECTION 1. Section 104101 is added to the Health and Safety Code, to read:104101. (a) The department shall establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension.(b) The task force shall do all of the following:(1) Develop and update a summary of the advances made in research on, and treatment and diagnosis of, pediatric pulmonary hypertension.(2) Develop and update a summary of the advances made in access to care for individuals with a diagnosis of pulmonary hypertension.(3) Monitor pulmonary hypertension research, services, and support activities across the state, including coordination of the states activities and programs with respect to pediatric pulmonary hypertension.(4) Develop and update a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension, including recommendations on how to do all of the following:(A) Advance research on pediatric and pulmonary hypertension.(B) Improve the transplantation criteria and process concerning both lung transplants and heart and lung transplants for individuals with a diagnosis of pulmonary hypertension.(C) Improve public awareness and recognition of pulmonary hypertension.(D) Improve health care delivery for individuals with a diagnosis of pulmonary hypertension.(E) Improve the early and accurate diagnosis of pediatric pulmonary hypertension.(F) Systematically advance the full spectrum of biomedical research on pulmonary hypertension.(5) Develop and update the progress made in implementing the comprehensive strategic plan developed pursuant to paragraph (4).(c) The task force shall be comprised of the following members:(1) The Secretary of California Health and Human Services or a designee, who shall serve as the chair of the task force.(2) The State Public Health Officer or a designee.(3) The Insurance Commissioner or a designee.(4) The Director of Health Care Services or a designee.(5) Eight additional members to be appointed by the secretary as follows:(A) Two representatives of the California Medical Association.(B) One representative of the California Association of Health Plans.(C) One representative from a commercial health insurance plan or managed care organization operating in the state.(D) One individual with a diagnosis of pulmonary hypertension or the parent or guardian of an individual with a diagnosis of pediatric pulmonary hypertension.(E) One representative of the California Chapter of the American College of Cardiology.(F) One representative of a pharmaceutical company that manufactures a drug or device for detecting, preventing, or treating pediatric pulmonary hypertension.(G) One representative of a research, advocacy, or support organization primarily serving individuals with a diagnosis of pediatric pulmonary hypertension.(d) Members of the task force shall serve without compensation. All administrative requirements for the production of the reports shall be completed by the California Health and Human Services Agency.(e) The task force shall submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023. The reports shall be submitted in compliance with Section 9795 of the Government Code.SECTION 1.Section 1695 of the Health and Safety Code is amended to read:1695.To the extent that funds are available in the State Department of Health Services budget for the 199495 fiscal year for this purpose, the department shall convene a consensus conference to address the issue of testing or treatment to prevent neonatal group B streptococcal disease (chemoprophylaxis). The conferees shall include, but not be limited to, representation from the California Chapter of the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists District IX, the California Medical Association, the California Conference of Local Health Officers, and the Group B Strep Association. The conference shall convene at least once during the 199495 fiscal year. The department shall develop, based on the proceedings of the consensus conference, a standardized written summary on group B streptococcal disease and guidelines on the prevention of neonatal group B streptococcal disease, no later than July 1, 1995. The department shall make every effort to obtain appropriate federal funds for this purpose, if the department determines that state funds are not available.
The people of the State of California do enact as follows:
## The people of the State of California do enact as follows:
SECTION 1. Section 104101 is added to the Health and Safety Code, to read:104101. (a) The department shall establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension.(b) The task force shall do all of the following:(1) Develop and update a summary of the advances made in research on, and treatment and diagnosis of, pediatric pulmonary hypertension.(2) Develop and update a summary of the advances made in access to care for individuals with a diagnosis of pulmonary hypertension.(3) Monitor pulmonary hypertension research, services, and support activities across the state, including coordination of the states activities and programs with respect to pediatric pulmonary hypertension.(4) Develop and update a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension, including recommendations on how to do all of the following:(A) Advance research on pediatric and pulmonary hypertension.(B) Improve the transplantation criteria and process concerning both lung transplants and heart and lung transplants for individuals with a diagnosis of pulmonary hypertension.(C) Improve public awareness and recognition of pulmonary hypertension.(D) Improve health care delivery for individuals with a diagnosis of pulmonary hypertension.(E) Improve the early and accurate diagnosis of pediatric pulmonary hypertension.(F) Systematically advance the full spectrum of biomedical research on pulmonary hypertension.(5) Develop and update the progress made in implementing the comprehensive strategic plan developed pursuant to paragraph (4).(c) The task force shall be comprised of the following members:(1) The Secretary of California Health and Human Services or a designee, who shall serve as the chair of the task force.(2) The State Public Health Officer or a designee.(3) The Insurance Commissioner or a designee.(4) The Director of Health Care Services or a designee.(5) Eight additional members to be appointed by the secretary as follows:(A) Two representatives of the California Medical Association.(B) One representative of the California Association of Health Plans.(C) One representative from a commercial health insurance plan or managed care organization operating in the state.(D) One individual with a diagnosis of pulmonary hypertension or the parent or guardian of an individual with a diagnosis of pediatric pulmonary hypertension.(E) One representative of the California Chapter of the American College of Cardiology.(F) One representative of a pharmaceutical company that manufactures a drug or device for detecting, preventing, or treating pediatric pulmonary hypertension.(G) One representative of a research, advocacy, or support organization primarily serving individuals with a diagnosis of pediatric pulmonary hypertension.(d) Members of the task force shall serve without compensation. All administrative requirements for the production of the reports shall be completed by the California Health and Human Services Agency.(e) The task force shall submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023. The reports shall be submitted in compliance with Section 9795 of the Government Code.
SECTION 1. Section 104101 is added to the Health and Safety Code, to read:
### SECTION 1.
104101. (a) The department shall establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension.(b) The task force shall do all of the following:(1) Develop and update a summary of the advances made in research on, and treatment and diagnosis of, pediatric pulmonary hypertension.(2) Develop and update a summary of the advances made in access to care for individuals with a diagnosis of pulmonary hypertension.(3) Monitor pulmonary hypertension research, services, and support activities across the state, including coordination of the states activities and programs with respect to pediatric pulmonary hypertension.(4) Develop and update a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension, including recommendations on how to do all of the following:(A) Advance research on pediatric and pulmonary hypertension.(B) Improve the transplantation criteria and process concerning both lung transplants and heart and lung transplants for individuals with a diagnosis of pulmonary hypertension.(C) Improve public awareness and recognition of pulmonary hypertension.(D) Improve health care delivery for individuals with a diagnosis of pulmonary hypertension.(E) Improve the early and accurate diagnosis of pediatric pulmonary hypertension.(F) Systematically advance the full spectrum of biomedical research on pulmonary hypertension.(5) Develop and update the progress made in implementing the comprehensive strategic plan developed pursuant to paragraph (4).(c) The task force shall be comprised of the following members:(1) The Secretary of California Health and Human Services or a designee, who shall serve as the chair of the task force.(2) The State Public Health Officer or a designee.(3) The Insurance Commissioner or a designee.(4) The Director of Health Care Services or a designee.(5) Eight additional members to be appointed by the secretary as follows:(A) Two representatives of the California Medical Association.(B) One representative of the California Association of Health Plans.(C) One representative from a commercial health insurance plan or managed care organization operating in the state.(D) One individual with a diagnosis of pulmonary hypertension or the parent or guardian of an individual with a diagnosis of pediatric pulmonary hypertension.(E) One representative of the California Chapter of the American College of Cardiology.(F) One representative of a pharmaceutical company that manufactures a drug or device for detecting, preventing, or treating pediatric pulmonary hypertension.(G) One representative of a research, advocacy, or support organization primarily serving individuals with a diagnosis of pediatric pulmonary hypertension.(d) Members of the task force shall serve without compensation. All administrative requirements for the production of the reports shall be completed by the California Health and Human Services Agency.(e) The task force shall submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023. The reports shall be submitted in compliance with Section 9795 of the Government Code.
104101. (a) The department shall establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension.(b) The task force shall do all of the following:(1) Develop and update a summary of the advances made in research on, and treatment and diagnosis of, pediatric pulmonary hypertension.(2) Develop and update a summary of the advances made in access to care for individuals with a diagnosis of pulmonary hypertension.(3) Monitor pulmonary hypertension research, services, and support activities across the state, including coordination of the states activities and programs with respect to pediatric pulmonary hypertension.(4) Develop and update a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension, including recommendations on how to do all of the following:(A) Advance research on pediatric and pulmonary hypertension.(B) Improve the transplantation criteria and process concerning both lung transplants and heart and lung transplants for individuals with a diagnosis of pulmonary hypertension.(C) Improve public awareness and recognition of pulmonary hypertension.(D) Improve health care delivery for individuals with a diagnosis of pulmonary hypertension.(E) Improve the early and accurate diagnosis of pediatric pulmonary hypertension.(F) Systematically advance the full spectrum of biomedical research on pulmonary hypertension.(5) Develop and update the progress made in implementing the comprehensive strategic plan developed pursuant to paragraph (4).(c) The task force shall be comprised of the following members:(1) The Secretary of California Health and Human Services or a designee, who shall serve as the chair of the task force.(2) The State Public Health Officer or a designee.(3) The Insurance Commissioner or a designee.(4) The Director of Health Care Services or a designee.(5) Eight additional members to be appointed by the secretary as follows:(A) Two representatives of the California Medical Association.(B) One representative of the California Association of Health Plans.(C) One representative from a commercial health insurance plan or managed care organization operating in the state.(D) One individual with a diagnosis of pulmonary hypertension or the parent or guardian of an individual with a diagnosis of pediatric pulmonary hypertension.(E) One representative of the California Chapter of the American College of Cardiology.(F) One representative of a pharmaceutical company that manufactures a drug or device for detecting, preventing, or treating pediatric pulmonary hypertension.(G) One representative of a research, advocacy, or support organization primarily serving individuals with a diagnosis of pediatric pulmonary hypertension.(d) Members of the task force shall serve without compensation. All administrative requirements for the production of the reports shall be completed by the California Health and Human Services Agency.(e) The task force shall submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023. The reports shall be submitted in compliance with Section 9795 of the Government Code.
104101. (a) The department shall establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension.(b) The task force shall do all of the following:(1) Develop and update a summary of the advances made in research on, and treatment and diagnosis of, pediatric pulmonary hypertension.(2) Develop and update a summary of the advances made in access to care for individuals with a diagnosis of pulmonary hypertension.(3) Monitor pulmonary hypertension research, services, and support activities across the state, including coordination of the states activities and programs with respect to pediatric pulmonary hypertension.(4) Develop and update a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension, including recommendations on how to do all of the following:(A) Advance research on pediatric and pulmonary hypertension.(B) Improve the transplantation criteria and process concerning both lung transplants and heart and lung transplants for individuals with a diagnosis of pulmonary hypertension.(C) Improve public awareness and recognition of pulmonary hypertension.(D) Improve health care delivery for individuals with a diagnosis of pulmonary hypertension.(E) Improve the early and accurate diagnosis of pediatric pulmonary hypertension.(F) Systematically advance the full spectrum of biomedical research on pulmonary hypertension.(5) Develop and update the progress made in implementing the comprehensive strategic plan developed pursuant to paragraph (4).(c) The task force shall be comprised of the following members:(1) The Secretary of California Health and Human Services or a designee, who shall serve as the chair of the task force.(2) The State Public Health Officer or a designee.(3) The Insurance Commissioner or a designee.(4) The Director of Health Care Services or a designee.(5) Eight additional members to be appointed by the secretary as follows:(A) Two representatives of the California Medical Association.(B) One representative of the California Association of Health Plans.(C) One representative from a commercial health insurance plan or managed care organization operating in the state.(D) One individual with a diagnosis of pulmonary hypertension or the parent or guardian of an individual with a diagnosis of pediatric pulmonary hypertension.(E) One representative of the California Chapter of the American College of Cardiology.(F) One representative of a pharmaceutical company that manufactures a drug or device for detecting, preventing, or treating pediatric pulmonary hypertension.(G) One representative of a research, advocacy, or support organization primarily serving individuals with a diagnosis of pediatric pulmonary hypertension.(d) Members of the task force shall serve without compensation. All administrative requirements for the production of the reports shall be completed by the California Health and Human Services Agency.(e) The task force shall submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023. The reports shall be submitted in compliance with Section 9795 of the Government Code.
104101. (a) The department shall establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension.
(b) The task force shall do all of the following:
(1) Develop and update a summary of the advances made in research on, and treatment and diagnosis of, pediatric pulmonary hypertension.
(2) Develop and update a summary of the advances made in access to care for individuals with a diagnosis of pulmonary hypertension.
(3) Monitor pulmonary hypertension research, services, and support activities across the state, including coordination of the states activities and programs with respect to pediatric pulmonary hypertension.
(4) Develop and update a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pediatric or pulmonary hypertension, including recommendations on how to do all of the following:
(A) Advance research on pediatric and pulmonary hypertension.
(B) Improve the transplantation criteria and process concerning both lung transplants and heart and lung transplants for individuals with a diagnosis of pulmonary hypertension.
(C) Improve public awareness and recognition of pulmonary hypertension.
(D) Improve health care delivery for individuals with a diagnosis of pulmonary hypertension.
(E) Improve the early and accurate diagnosis of pediatric pulmonary hypertension.
(F) Systematically advance the full spectrum of biomedical research on pulmonary hypertension.
(5) Develop and update the progress made in implementing the comprehensive strategic plan developed pursuant to paragraph (4).
(c) The task force shall be comprised of the following members:
(1) The Secretary of California Health and Human Services or a designee, who shall serve as the chair of the task force.
(2) The State Public Health Officer or a designee.
(3) The Insurance Commissioner or a designee.
(4) The Director of Health Care Services or a designee.
(5) Eight additional members to be appointed by the secretary as follows:
(A) Two representatives of the California Medical Association.
(B) One representative of the California Association of Health Plans.
(C) One representative from a commercial health insurance plan or managed care organization operating in the state.
(D) One individual with a diagnosis of pulmonary hypertension or the parent or guardian of an individual with a diagnosis of pediatric pulmonary hypertension.
(E) One representative of the California Chapter of the American College of Cardiology.
(F) One representative of a pharmaceutical company that manufactures a drug or device for detecting, preventing, or treating pediatric pulmonary hypertension.
(G) One representative of a research, advocacy, or support organization primarily serving individuals with a diagnosis of pediatric pulmonary hypertension.
(d) Members of the task force shall serve without compensation. All administrative requirements for the production of the reports shall be completed by the California Health and Human Services Agency.
(e) The task force shall submit a report to the Governors office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023. The reports shall be submitted in compliance with Section 9795 of the Government Code.
To the extent that funds are available in the State Department of Health Services budget for the 199495 fiscal year for this purpose, the department shall convene a consensus conference to address the issue of testing or treatment to prevent neonatal group B streptococcal disease (chemoprophylaxis). The conferees shall include, but not be limited to, representation from the California Chapter of the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists District IX, the California Medical Association, the California Conference of Local Health Officers, and the Group B Strep Association. The conference shall convene at least once during the 199495 fiscal year. The department shall develop, based on the proceedings of the consensus conference, a standardized written summary on group B streptococcal disease and guidelines on the prevention of neonatal group B streptococcal disease, no later than July 1, 1995. The department shall make every effort to obtain appropriate federal funds for this purpose, if the department determines that state funds are not available.